Drug Profile
Florbetaben F18 - Piramal
Alternative Names: 18F-AV 1; 18F-AV1/ZK; [18F] florbetaben; AV-1; AV-1/ZK; BAY 94-9172; Florbetaben 18F; florbetaben18F; NeuraCeq; Neuraceq; UNII-TLA7312TOI; ZK 6013443Latest Information Update: 19 Dec 2023
Price :
$50
*
At a glance
- Originator Avid Radiopharmaceuticals
- Developer Avid Radiopharmaceuticals; Bayer HealthCare Pharmaceuticals; Ci-Co Healthcare; FONDAZIONE TOSCANA GABRIELE MONASTERIO; Isologic Innovative Radiopharmaceuticals; PET Pharm Biotech; Piramal Enterprises; Sinotau Pharmaceuticals
- Class Aniline compounds; Radiopharmaceutical diagnostics; Small molecules
- Mechanism of Action Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Alzheimer's disease
- Phase III Amyloidosis
- Phase II Cardiovascular disorders
- Discontinued Mild cognitive impairment
Most Recent Events
- 13 Dec 2023 Launched for Alzheimer's disease (Diagnosis) in Japan (IV)
- 13 Dec 2023 Japanese Ministry of Health approves the reimbursement by governmental health insurance of the amyloid Positron Emission Tomography (PET) diagnostic Neuraceq® (florbetaben 18F)
- 22 Nov 2023 Registered for Alzheimer's disease (Diagnosis) in Japan (IV)